Conference Coverage
Conference Coverage
Black race linked to poorer survival in AML
Conference Coverage
Cost is the main hurdle to broad use of caplacizumab for TTP
“If we take finances out, I think almost every patient except those with a bleeding risk or bleeding problem should get it,” an investigator said...
Conference Coverage
No benefit from tranexamic acid prophylaxis in blood cancers
Conference Coverage
Childhood Hodgkin survivors have neurocognitive impairment
Conference Coverage
SABCS 2020: What’s hot, including a major chemotherapy trial
The world’s largest breast cancer meeting starts on Dec. 8.
Conference Coverage
Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patients
Conference Coverage
Durable responses with anti-BCMA CAR T-cell for multiple myeloma
Seventy-two percent of patients with relapsed/refractory multiple myeloma had ongoing responses at the time of data cutoff in the CARTITUDE-1...
Conference Coverage
Allogeneic transplant leads to durable remissions in T-cell lymphomas
Retrospective study demonstrates overall survival over 50% at 5 years, though transplant-related mortality and graft-versus-host disease need to...
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry